Menu
Menu
What does teaching a robot to drive on Mars have to do with curing cancer?
In this episode of Decoded, Dr. Jurgi Camblong speaks with Thomas Fuchs, a pioneer who proves that with the right data, we can solve any problem.
Starting his career at NASA's Jet Propulsion Laboratory , Thomas built AI for the Spirit and Opportunity Mars rovers. He then brought that same engineering mindset to oncology, moving from Caltech to Memorial Sloan Kettering. He is rewriting the rules of medicine, having won the first-ever FDA approval for AI in pathology and now spearheading Eli Lilly's $1 billion generative AI collaboration with NVIDIA.
You’ll hear about:
This episode explores how we are moving into a new era of medicine , where better outcomes come not just from algorithms alone, but from the pioneers who are brave enough to trust them.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
